Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller
« Previous
123456789101112
Next »

Sizing the Market for Contract Manufacturing

Measuring the size of the market for contract manufacturing services requires a careful hand.
Oct 2, 2012
By: Jim Miller

Measuring the size of the market for contract manufacturing services requires a careful hand.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Sep 2, 2012
By: Jim Miller

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Sep 1, 2012
By: Jim Miller

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

CROs and CMOs Have Cause to Celebrate

Annual survey shows strong growth for service providers and promises to continue into 2013. This article is part of a special issue on outsourcing.
Aug 1, 2012
By: Jim Miller

Annual survey shows strong growth for service providers and promises to continue into 2013.

Channeling Steve Jobs

Service providers must focus on delivering a superior customer experience.
May 2, 2012
By: Jim Miller

Service providers must focus on delivering a superior customer experience.

Channeling Steve Jobs

Service providers must focus on delivering a superior customer experience.
May 1, 2012
By: Jim Miller

Service providers must focus on delivering a superior customer experience.

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Apr 4, 2012
By: Jim Miller

The evolving bio/pharmaceutical business model poses risk for CMOs.

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Mar 2, 2012
By: Jim Miller

The evolving bio/pharmaceutical business model poses risk for CMOs.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Feb 1, 2012
By: Jim Miller

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

« Previous
123456789101112
Next »

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here